Company intelligence / Profile preview

Protalex, Inc.

Florham Park, New Jersey, United Statesprotalex.com ↗
Ownership
Private
Development stage
Other
01

Overview

PRTX-100 has demonstrated safety and tolerability at all dose levels in PRTX-100-103 and PRTX-100-104 studies

Therapeutic areas
HematologyImmunologyDermatologyNeurology
Modalities
Biopharmaceutical drugsProtein-based therapeutics
Industry
Biotech
02

Drug pipeline

1 asset

staphylococcal protein a

2

Beyond the preview

Go deeper on Protalex, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protalex, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call